AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26392095
Drug: Granulocyte Colony-Stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte Colony-Stimulating Factor (G-CSF)
Trial: 28661585
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300 U/mL (Gla‐300) morning injection
Trial: 28661585
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 U/mL (Gla‐100) evening injection
Trial: 15728225
Drug: Novel six-drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel six-drug combination chemotherapy for stage III disease
Trial: 15728225
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without alkylating agents for genitourinary nonbladder prostate tumors
Trial: 15728225
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment strategy including selective avoidance of local therapy
Trial: 15728225
Drug: Previous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previous treatment strategy (MMT 84)
Trial: 10989464
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron 5 mg/m2 plus dexamethasone 2-4 mg p.o.
Trial: 10989464
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron 8 mg syrup plus dexamethasone 2-4 mg p.o.
Trial: 9185752
Drug: L-ornithine-L-aspartate (OA)
RxNorm normalized name: ornithine, (L)-isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine-L-aspartate (OA) 20 g/d, infused intravenously for 4 hours over 7 consecutive days
Trial: 9185752
Drug: L-ornithine-L-aspartate (OA)
RxNorm normalized name: ornithine, (L)-isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine-L-aspartate (OA) 20 g/d
Trial: 1588146
Drug: Bacterial polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial polysaccharide immune globulin (BPIG) at a dose of 0.5 ml/kg
Trial: 1588146
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of diphtheria‐tetanus‐pertussis or Hib oligosaccharide‐diphtheria CRM197 conjugate vaccines
Trial: 3896099
Drug: Ceruletide (cholecystokinin‐like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceruletide (cholecystokinin‐like peptide) administered intramuscularly twice a day for 4 consecutive days to schizophrenic patients.
Trial: 3896099
Drug: Ceruletide (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceruletide (0.3 micrograms/kg or 0.6 micrograms/kg) administered intramuscularly to normal volunteers.
Trial: 3896099
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo administered intramuscularly to normal volunteers.
Trial: 27539717
Drug: 5% acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% acyclovir cream (test product T)
Trial: 27539717
Drug: 5% acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% acyclovir cream (reference product R)
Trial: 20889359
Drug: Active local
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active local treatment (injection/hydroelectrophoresis)
Trial: 20889359
Drug: Placebo local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo local treatment
Trial: 20889359
Drug: Active local
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active local treatment (days 8 and 11) requested by placebo group
Trial: 20889359
Drug: Active therapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active therapy at 3-week follow-up
Trial: 16233932
Drug: Nicotinamide (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (1200 mg m(‐2) day(‐1))
Trial: 12065742
Drug: Ro 32-7315
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 32-7315 (2.5 mg/kg, i.p., twice daily)
Trial: 12065742
Drug: Ro 32-7315
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 32-7315 (5 mg/kg, i.p., twice daily)
Trial: 12065742
Drug: Ro 32-7315
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 32-7315 (10 mg/kg, i.p., twice daily)
Trial: 12065742
Drug: Ro 32-7315
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 32-7315 (20 mg/kg, i.p., twice daily)
Trial: 12065742
Drug: Ro 32-7315
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 32-7315 (450 mg, oral, single dose)
Trial: 12065742
Drug: Ro 32-7315
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 32-7315 (dose-dependent)
Trial: 7751529
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray 0.06%, 84 micrograms per nostril three times a day for the first 6 months, with possible dose reduction in the last 6 months.
Trial: 7751529
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray 0.06%
Trial: 2301192
Drug: Drug bulletin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug bulletin on renal colic treatment
Trial: 2301192
Drug: Drug bulletin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug bulletin on irritable bowel syndrome (IBS) treatment
Trial: 6772011
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (50 mg of elemental zinc as zinc acetate per day)
Trial: 31837906
Drug: Intramuscular ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular ondansetron 0.1 mg/kg plus ketamine 4 mg/kg
Trial: 31837906
Drug: Ketamine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 4 mg/kg (control group)
Trial: 23623914
Drug: Low-dose sodium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sodium nitrite (NaNO₂) (1.5 μmol/min for 20 min)
Trial: 23623914
Drug: Low-dose sodium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sodium nitrite (NaNO₂) before ischemia
Trial: 23623914
Drug: Low-dose sodium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sodium nitrite (NaNO₂) during reperfusion
Trial: 18990175
Drug: Solifenacin 5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5/10 mg
Trial: 17158411
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and exercise therapy (treatment group)
Trial: 14574034
Drug: Oral dofetilide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dofetilide, oral bolus-flecainide, propafenone, intravenous ibutilide
Trial: 14574034
Drug: Rate control
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rate control drugs
Trial: 10717333
Drug: Topotecan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan at intravenous doses of 1.5 mg/m(2)/day over 30 min for 5 days every 3 weeks (Arm A)
Trial: 10717333
Drug: Topotecan at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan at intravenous doses of 1.3 mg/m(2) for 5 days every 3 weeks (Arm B)
Trial: 10717333
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A (1.5 mg/m(2)/day)
Trial: 10717333
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B (1.3 mg/m(2))
Trial: 1677368
Drug: Dopexamine (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine (high dose: 4 micrograms/kg/min)
Trial: 1677368
Drug: Dopexamine (intermediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine (intermediate dose: 2 micrograms/kg/min)
Trial: 1677368
Drug: Dopexamine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine (low dose: 1 microgram/kg/min)
Trial: 6137386
Drug: Lormetazepam 0.5
RxNorm normalized name: lormetazepam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam 0.5 mg
Trial: 31867608
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave therapy (0.2 mJ/mm2) once a week for four weeks in addition to standard physical rehabilitation (n = 12)
Trial: 31867608
Drug: Botulinum toxin‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin‐A injection (0.5-2 U/kg/muscle group with maximum dose of 12 U/kg/body weight) once at entry besides standard physical rehabilitation (n = 13)
Trial: 31365529
Drug: 1.8 mL
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mL of PDL injection
Trial: 31365529
Drug: 3.6 mL
RxNorm normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mL of PDL injection
Trial: 27054365
Drug: Catheterization threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheterization threshold of 500 ml
Trial: 27054365
Drug: Catheterization threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheterization threshold of 800 ml
Trial: 22155768
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (qHPV vaccine; Gardasil)
Trial: 18489430
Drug: Computer-assisted dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted dosage
Trial: 18489430
Drug: Medical staff
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medical staff dosage
Trial: 12803269
Drug: metoprolol 2
RxNorm normalized name: metoprolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol 2 mg
Trial: 12803269
Drug: lidocaine 20
RxNorm normalized name: lidocaine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine 20 mg
Trial: 12803269
Drug: saline 2
RxNorm normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline 2 mL
Trial: 22256639
Drug: Routine complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine complex treatment
Trial: 1599352
Drug: Single-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose therapy with norfloxacin (800 mg)
Trial: 1599352
Drug: 3-day therapy
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day therapy with norfloxacin (400 mg twice daily)
Trial: 6327800
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (200 or 400 mg oral dose)
Trial: 6327800
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (600-1000 mg/day, long-term administration)
Trial: 31492603
Drug: Succinylated gelatin
RxNorm normalized name: Succinylated gelatin
DrugBank: Succinylated gelatin (DB16568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylated gelatin infusion (10 ml/kg)
Trial: 31492603
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate infusion
Trial: 31492603
Drug: Succinylated gelatin
RxNorm normalized name: Succinylated gelatin
DrugBank: Succinylated gelatin (DB16568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylated gelatin infusion
Trial: 29557399
Drug: 4.0 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mm long implants
Trial: 29557399
Drug: 10.0 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.0 mm long implants
Trial: 27144672
Drug: Post-operative RT
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative RT with TST/NMES therapy (Group II)
Trial: 23234816
Drug: Chlorella group
RxNorm normalized name: Chlorella emersonii extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorella group (C. vulgaris extract 1200 mg/day + metformin 750 mg/day + vitamin E 200 mg/day for 3 months)
Trial: 23234816
Drug: Metformin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin group (metformin 1250 mg/day + vitamin E 200 mg/day for 3 months)
Trial: 15659542
Drug: Daptomycin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daptomycin (4 mg/kg every 24 h intravenously for 7-14 days)
Trial: 10342225
Drug: Fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk product containing 10(7) cfu/ml L. johnsonii La1 (group B)
Trial: 10342225
Drug: Fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk product containing 10(6) cfu/ml L. johnsonii La1 (group C)
Trial: 7875642
Drug: Nefazodone (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone (50, 100, and 200 mg)
Trial: 29307527
Drug: Multisystemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisystemic therapy followed by management as usual
Trial: 23596055
Drug: Weekly carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly carboplatin and paclitaxel with radiation
Trial: 23596055
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin and radiation
Trial: 23596055
Drug: Weekly chemotherapy
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly chemotherapy and radiation
Trial: 23596055
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by high-dose cisplatin and radiation
Trial: 15911548
Drug: Fosfomycin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin (single dose)
Trial: 12644731
Drug: Acamprosate therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate therapy
Trial: 12644731
Drug: Standard cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard cohort (no pharmacotherapy)
Trial: 10596714
Drug: Oral levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral levofloxacin (300 mg b.i.d.)
Trial: 10596714
Drug: Intravenous ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ceftazidime (1 g i.v. t.d.)
Trial: 6742528
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with a commercial standardized aluminum hydroxide‐bound dog dander extract (15 subjects)
Trial: 6742528
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections containing histamine (12 subjects)
Trial: 31831074
Drug: Biopsychosocial multidisciplinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biopsychosocial multidisciplinary intervention (physiotherapy, cognitive-behavioral therapy, medication)
Trial: 12479191
Drug: Esmolol 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol 1.0 mg x kg(‐1) and Nicardipine 30 microg x kg(‐1)
Trial: 8545860
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) 1‐2 mg/kg/day
Trial: 28561987
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol and Foleys catheter
Trial: 25327872
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol alone
Trial: 17426465
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg, n=30)
Trial: 12108888
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment modifications including extent of staging work-up, radiation field size and dose, optimal chemotherapy regimen, number of cycles of chemotherapy, limited- vs extended-field radiation therapy and dose.
Trial: 12108888
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone in early-stage patients.
Trial: 9796090
Drug: Low-dose estradiol-releasing
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose estradiol-releasing vaginal ring
Trial: 2523663
Drug: Isradipine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (various doses)
Trial: 2523663
Drug: Isradipine (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (doses above 10 mg per day)
Trial: 1071960
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diuretic and propranolol
Trial: 19736165
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (aspirin, thienopyridine, cilostazol)
Trial: 7584277
Drug: Faces with
RxNorm normalized name: Face Up with Sulfur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faces with two names (e.g., actors playing nameable characters)
Trial: 29685815
Drug: Eculizumab (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (900 mg)
Trial: 25023799
Drug: DRC-based diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRC-based diet with 0% WDGS and 84 mg/steer ZH
Trial: 25023799
Drug: DRC-based diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRC-based diet with 30% WDGS and 84 mg/steer of ZH
Trial: 18261965
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg (BMI ≤50 kg/m2) or 60 mg (BMI >50 kg/m2) every 12 hours during hospitalization and once daily for 10 days after discharge
Trial: 7488301
Drug: Retard capsule
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retard capsule containing 20 mg PE hydrochloride and 4 mg CA maleate
Trial: 7488301
Drug: Aqueous solution
RxNorm normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution of the same active principles
Trial: 7488301
Drug: Retard capsule
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retard capsule under repeated dosing conditions (one capsule b.i.d. during 4 days)
Trial: 2298357
Drug: Laxative preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative preparation
Trial: 2298357
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no laxative preparation)
Trial: 6155029
Drug: Zinc sulfate,
RxNorm normalized name: Zinc sulfate, anhydrous
DrugBank: Zinc sulfate (DB09322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc sulfate, 440 mg total daily dose
Trial: 30931663
Drug: Hi-Fatigue G
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hi-Fatigue G
Trial: 22422304
Drug: Cholecalciferol 2,000
RxNorm normalized name: CHOLECALCIFEROL 2,000UNIT TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 2,000 IU daily
Trial: 22422304
Drug: Cholecalciferol 5,000
RxNorm normalized name: CHOLECALCIFEROL 5,000UNIT CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 5,000 IU daily
Trial: 21542916
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment as recommended by 4‐T staff
Trial: 21542916
Drug: 4‐T automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐T automated insulin dose adjustment algorithm
Trial: 17151589
Drug: Spread 1
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spread 1 (200 microg folic acid, 2 microg vitamin B(12), 1 mg vitamin B(6))
Trial: 17151589
Drug: Spread 2
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spread 2 (400 microg folic acid, 2 microg vitamin B(12), 1 mg vitamin B(6))